New hope for tough liver cancers: trial tests Next-Line combo
NCT ID NCT07219459
Summary
This study is for people with advanced liver cancer that has spread or cannot be removed by surgery, and whose cancer has gotten worse after their first treatment, which included a type of immunotherapy. It will test if adding a new investigational drug called visugromab to a standard two-drug regimen is more effective and safe than the standard regimen alone. The goal is to see if this new combination can better control the cancer's growth and extend the time people live without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.